PDS Biotechnology Corp
PDSB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472091
No open-market purchases or sales by PDS Biotechnology Corp insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $6.78M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by PDS Biotechnology Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for PDS Biotechnology Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Brawley Otis W | Director | – | Mar 3, 2026 | 1 |
| Glover Steve C | Director | 78,851 | Mar 3, 2026 | 1 |
| Boesgaard Lars | Chief Financial Officer | – | Mar 3, 2026 | 1 |
| Freitag Gregory Gene | Director | 61,213 | Mar 3, 2026 | 1 |
| Ali-Jackson Kamil | Director | – | Mar 3, 2026 | 1 |
| Toutain Stephan | Chief Operating Officer | – | Mar 3, 2026 | 1 |
| Conn Gregory | Chief Scientific Officer | – | Mar 3, 2026 | 1 |
| Bedu-Addo Frank | President/CEO | 690,866 | Mar 3, 2026 | 1 |
| Iliev Ilian | Director | – | Mar 3, 2026 | 1 |
| Brown Spencer D. | Senior VP, General Counsel | – | Mar 3, 2026 | 1 |
| Shepard Kirk V. | Chief Medical Officer | – | Mar 3, 2026 | 1 |
| Sykes Richard | Director | – | Jun 25, 2024 | 0 |
| Hill Matthew C | Chief Financial Officer | 4,075Indirect | Jan 6, 2023 | 0 |
| Wood Lauren | Chief Medical Officer | – | Jan 6, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Freitag Gregory GeneDirector | PPurchase | +15.1K | $1.66 | +$25.0K | +32.6%61.2K after | |
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Freitag Gregory GeneDirector | PPurchase | +15.1K | – | – | –15.1K after | Derivative |
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Glover Steve CDirector | PPurchase | +15.1K | $1.66 | +$25.0K | +23.6%78.9K after | |
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Glover Steve CDirector | PPurchase | +15.1K | – | – | –15.1K after | Derivative |
| Dec 14, 2021 (view filing) | Dec 13 | 1 day | Hill Matthew CChief Financial Officer | PPurchase | +2.90K | $8.99 | +$26.1K | +297.4%3.88K after | 2 lots |
| Dec 14, 2021 (view filing) | Dec 13 | 1 day | Hill Matthew CChief Financial Officer | PPurchase | +200 | $9.00 | +$1.80K | +5.2%4.08K after | 2 lots |